

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA PRECIOUS METAL RESOURCES HOLDINGS CO., LTD.**

**中國貴金屬資源控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 1194)

**CHANGE OF CHIEF FINANCIAL OFFICER AND  
AUTHORISED REPRESENTATIVE  
AND  
RESIGNATION OF COMPANY SECRETARY**

The Board announces that with effect from 20 September 2016:

1. Dr. SHI has been appointed as the chief financial officer of the Company;
2. Mr. Zhang, an executive Director and the chief financial officer of the Company, has resigned as the chief financial officer of the Company, but remains as an executive Director.
3. Mr. Liu has been appointed to act as an authorised representative of the Company under the Listing Rules; and
4. Ms. Tam has resigned as the company secretary and an authorised representative of the Company under the Listing Rules.

**CHANGE OF CHIEF FINANCIAL OFFICER**

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of China Precious Metal Resources Holdings Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Zhang Liwei (“**Mr. Zhang**”), an executive Director and the chief financial officer of the Company, has resigned as the chief financial officer of the Company with effect from 20 September 2016. Mr. Zhang remains as an executive Director of the Company.

The Board is pleased to announce that Dr. SHI, Simon Hao (“**Dr. SHI**”) has been appointed as the chief financial officer of the Company with effect from 20 September 2016.

The biographical details of Dr. SHI is set out as below:

Dr. SHI, aged 52, has over 15 years of experience in financial management, fund and asset management. Prior to joining the Company, Dr. SHI has served various international investment groups and public-listed companies in the PRC, Taiwan and Hong Kong holding various positions such as manager, financial controller, vice president, and chief financial officer. Dr. SHI was an executive director and chief financial officer of Munsun Assets Management Limited (which is interested in an aggregate of 2,585,447,189 shares in the Company representing approximately 18.66% of the total issued share capital of the Company as at date of this announcement pursuant to Part XV of the Securities and Future Ordinance (Cap. 571, Laws of Hong Kong) (the “SFO”), ) between November 2012 and September 2015. He was appointed as a financial officer of the Company in September 2015 and is at present the director of Munsun Securities Limited, a wholly owned subsidiary of the Company. He was appointed as an non-executive director of L’Sea Resources International Holdings Limited, a company listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) on April 1, 2014, and was re-designated as an executive director on March 31, 2015.

Dr. SHI graduated from Fudan University with a bachelor’s degree in Biophysics in 1987 and obtained a PhD degree at State University of New York Downstate Medical School in 1995, followed by a postdoctoral fellowship at an affiliate hospital of Harvard Medical School, Harvard University in 1998. Dr. SHI received his MBA degree from University of Southern California Marshall School of Business in 2000.

To the best knowledge of the Board and save as disclosed above, as at the date of this announcement, (i) Dr. SHI does not have any relationship with any director, senior management, substantial shareholders or controlling shareholders of the Company; (ii) Dr. SHI has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) Dr. SHI does not hold any other positions in the Company or other members of the Group; and (iv) Dr. SHI does not have, and is not deemed to have any other interests or short positions in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no matter relating to the appointment of Dr. SHI that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange nor any information that should be disclosed pursuant to paragraph 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities (the “**Listing Rules**”).

### **CHANGE OF AUTHORISED REPRESENTATIVE**

The Board announces that Mr. Liu Liyang (“**Mr. Liu**”), an executive director of the Company has been appointed as an authorised representative of the Company under the Listing Rules with effect from 20 September 2016.

### **RESIGNATION OF COMPANY SECRETARY**

The Board also announces that Ms. Tam Pui Ling (“**Ms. Tam**”) has resigned as the company secretary of the Company and an authorised representative of the Company under the Listing Rules with effect from 20 September 2016. Ms. Tam has confirmed that she has no disagreement with the Board and there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is in the process of identifying a suitable candidate to fill the vacancy of company secretary and further announcement will be made after confirmation of such appointment.

The Board would like to express its appreciation to Mr. Zhang and Ms. Tam for their contributions to the Company during their tenure of office and welcome Mr. Liu and Dr. SHI for their new appointments.

By order of the Board of  
**China Precious Metal Resources Holdings Co., Ltd.**  
**LI Xianghong**  
*Chairman & Chief Executive Officer*

Hong Kong, 20 September 2016

*As at the date of this announcement, the executive directors of the Company are Mr. Li Xianghong, Mr. Liu Liyang, Mr. Wang Hao, Mr. Zhang Liwei, Mr. Zhang Lirui and Mr. Zhang Shuguang; and the independent non-executive directors of the Company are Mr. Wong Lung Tak Patrick, BBS, PhD, J.P., Mr. Chan Kin Sang and Mr. Xiao Rong Ge.*